HC Wainwright Issues Positive Forecast for ESPR Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Esperion Therapeutics to ($0.11), improving from the previous estimate of ($0.16), and maintains a "Buy" rating with a price target of $16.00.
• Esperion reported $82.39 million in revenue for Q3, surpassing expectations, and posted earnings of ($0.02) per share, outperforming analyst estimates of ($0.17).
• Institutional investors own 47.39% of Esperion's stock, with JPMorgan Chase increasing its stake by 18.6% in the last quarter.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, August 5th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($0.11) per share for the quarter, up from their previous estimate of ($0.16). HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.59 EPS and FY2028 earnings at $0.85 EPS.

ESPR has been the topic of a number of other research reports. The Goldman Sachs Group dropped their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Wall Street Zen raised shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Esperion Therapeutics Stock Down 3.8%

Shares of NASDAQ ESPR traded down $0.07 during trading on Friday, reaching $1.78. 3,506,740 shares of the company traded hands, compared to its average volume of 4,770,309. The stock has a market capitalization of $351.81 million, a PE ratio of -3.62 and a beta of 0.82. The firm has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.31. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The firm had revenue of $82.39 million for the quarter, compared to the consensus estimate of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after buying an additional 385,099 shares during the last quarter. Bank of America Corp DE raised its position in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock valued at $3,586,000 after buying an additional 506,428 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $98,000. D. E. Shaw & Co. Inc. raised its position in shares of Esperion Therapeutics by 152.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 251,592 shares of the biopharmaceutical company's stock valued at $554,000 after buying an additional 152,019 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Esperion Therapeutics by 65.7% during the fourth quarter. MetLife Investment Management LLC now owns 117,732 shares of the biopharmaceutical company's stock valued at $259,000 after buying an additional 46,682 shares during the last quarter. Institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.